

**Experiment Number:** 20215-02  
**Test Type:** 14-DAY  
**Route:** GAVAGE  
**Species/Strain:** Mouse/B6C3F1

**P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH  
AVERAGE SEVERITY GRADES[b]**  
**Test Compound:** tert-Butyl hydroperoxide  
**CAS Number:** 75-91-2

**Date Report Requested:** 10/18/2014  
**Time Report Requested:** 19:44:13  
**First Dose M/F:** NA / NA  
**Lab:** BAT

<b>C Number:</b>	C20215B
<b>Lock Date:</b>	04/27/2005
<b>Cage Range:</b>	All
<b>Date Range:</b>	All
<b>Reasons For Removal:</b>	All
<b>Removal Date Range:</b>	All
<b>Treatment Groups:</b>	All
<b>Study Gender:</b>	Both
<b>PWG Approval Date</b>	NONE

**Experiment Number:** 20215-02  
**Test Type:** 14-DAY  
**Route:** GAVAGE  
**Species/Strain:** Mouse/B6C3F1

**P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH  
AVERAGE SEVERITY GRADES[b]**  
**Test Compound:** tert-Butyl hydroperoxide  
**CAS Number:** 75-91-2

**Date Report Requested:** 10/18/2014  
**Time Report Requested:** 19:44:13  
**First Dose M/F:** NA / NA  
**Lab:** BAT

B6C3F1 Mouse MALE	0	MG/KG	22	MG/KG	44	MG/KG	88	MG/KG	176	MG/KG	350	MG/KG
<b>Disposition Summary</b>												
Animals Initially In Study	5		5		5		5		5		5	
Early Deaths												
Survivors												
Natural Death			1									
Terminal Sacrifice	5		4		5		5		5		5	
Animals Examined Microscopically	5		5		5		5		5		5	
<b>ALIMENTARY SYSTEM</b>												
Esophagus	(5)		(0)		(5)		(5)		(5)		(5)	
Epithelium, Hyperplasia							1 [1.0]		3 [1.0]		5 [1.2]	
Muscularis, Degeneration	1 [1.0]											
Liver	(5)		(5)		(5)		(5)		(5)		(5)	
Hematopoietic Cell Proliferation	1 [1.0]											
Inflammation, Chronic Active	3 [1.0]		4 [1.0]		5 [1.0]		5 [1.0]		5 [1.0]		3 [1.0]	
Mineralization											1 [1.0]	
Stomach, Forestomach	(5)		(5)		(5)		(5)		(5)		(5)	
Epithelium, Hyperplasia					3 [1.0]		4 [1.0]		5 [2.8]		5 [2.4]	
Inflammation									5 [1.6]		4 [2.0]	
Stomach, Glandular	(5)		(0)		(0)		(0)		(0)		(5)	
Inflammation											1 [1.0]	
<b>CARDIOVASCULAR SYSTEM</b>												
None												
<b>ENDOCRINE SYSTEM</b>												
None												
<b>GENERAL BODY SYSTEM</b>												
None												

a - Number of animals examined microscopically at site and number of animals with lesion  
b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

**Experiment Number:** 20215-02  
**Test Type:** 14-DAY  
**Route:** GAVAGE  
**Species/Strain:** Mouse/B6C3F1

**P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH  
AVERAGE SEVERITY GRADES[b]**  
**Test Compound:** tert-Butyl hydroperoxide  
**CAS Number:** 75-91-2

**Date Report Requested:** 10/18/2014  
**Time Report Requested:** 19:44:13  
**First Dose M/F:** NA / NA  
**Lab:** BAT

B6C3F1 Mouse MALE	0	MG/KG	22	MG/KG	44	MG/KG	88	MG/KG	176	MG/KG	350	MG/KG
GENITAL SYSTEM												
None												
HEMATOPOIETIC SYSTEM												
None												
INTEGUMENTARY SYSTEM												
None												
MUSCULOSKELETAL SYSTEM												
None												
NERVOUS SYSTEM												
None												
RESPIRATORY SYSTEM												
None												
SPECIAL SENSES SYSTEM												
None												
URINARY SYSTEM												
Kidney	(5)		(0)		(0)		(0)		(0)		(5)	
Mineralization	1 [1.0]											
Nephropathy											1 [1.0]	
Urinary Bladder	(5)		(0)		(0)		(0)		(0)		(5)	

\*\*\*END OF MALE DATA\*\*\*

a - Number of animals examined microscopically at site and number of animals with lesion  
b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Experiment Number: 20215-02

Test Type: 14-DAY

Route: GAVAGE

Species/Strain: Mouse/B6C3F1

**P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH  
AVERAGE SEVERITY GRADES[b]**

Test Compound: tert-Butyl hydroperoxide

CAS Number: 75-91-2

Date Report Requested: 10/18/2014

Time Report Requested: 19:44:13

First Dose M/F: NA / NA

Lab: BAT

B6C3F1 Mouse FEMALE	0	MG/KG	22	MG/KG	44	MG/KG	88	MG/KG	176	MG/KG	350	MG/KG
<b>Disposition Summary</b>												
Animals Initially In Study	5		5		5		5		5		5	
Early Deaths												
Survivors												
Terminal Sacrifice	5		5		5		5		5		5	
Animals Examined Microscopically	5				5		5		5		5	
<b>ALIMENTARY SYSTEM</b>												
Esophagus	(5)		(0)		(0)		(0)		(0)		(5)	
Liver	(5)		(0)		(0)		(0)		(5)		(5)	
Hematopoietic Cell Proliferation											1 [1.0]	
Hepatocyte, Hypertrophy											3 [1.0]	
Inflammation, Chronic Active	5 [1.0]								5 [1.0]		5 [1.0]	
Stomach, Forestomach	(5)		(0)		(5)		(5)		(5)		(5)	
Epithelium, Hyperplasia							3 [1.0]		5 [2.0]		5 [2.6]	
Inflammation									2 [1.5]		2 [2.0]	
Stomach, Glandular	(5)		(0)		(0)		(0)		(0)		(5)	
Epithelium, Cyst	1 [1.0]											
Glands, Metaplasia, Squamous											1 [1.0]	
<b>CARDIOVASCULAR SYSTEM</b>												
None												
<b>ENDOCRINE SYSTEM</b>												
None												
<b>GENERAL BODY SYSTEM</b>												
None												
<b>GENITAL SYSTEM</b>												
None												

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

**Experiment Number:** 20215-02  
**Test Type:** 14-DAY  
**Route:** GAVAGE  
**Species/Strain:** Mouse/B6C3F1

**P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH  
AVERAGE SEVERITY GRADES[b]**  
**Test Compound:** tert-Butyl hydroperoxide  
**CAS Number:** 75-91-2

**Date Report Requested:** 10/18/2014  
**Time Report Requested:** 19:44:13  
**First Dose M/F:** NA / NA  
**Lab:** BAT

B6C3F1 Mouse FEMALE	0	MG/KG	22	MG/KG	44	MG/KG	88	MG/KG	176	MG/KG	350	MG/KG
HEMATOPOIETIC SYSTEM	None											
INTEGUMENTARY SYSTEM	None											
MUSCULOSKELETAL SYSTEM	None											
NERVOUS SYSTEM	None											
RESPIRATORY SYSTEM	None											
SPECIAL SENSES SYSTEM	None											
URINARY SYSTEM												
Kidney	(5)		(0)		(0)		(0)		(0)		(5)	
Mineralization	2 [1.0]											
Nephropathy											1 [1.0]	
Urinary Bladder	(5)		(0)		(0)		(0)		(0)		(5)	
Hemorrhage											1 [2.0]	

**\*\* END OF REPORT \*\***

a - Number of animals examined microscopically at site and number of animals with lesion  
b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)